Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with (111)In, (177)Lu or (90)Y incorporated into tissue implantable depots.
Phys Med Biol. 2017 Oct 27;62(22):8581-8599
(64)Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
Mol Pharm. 2017 Feb 06;14(2):492-501
Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with <sup>111</sup>In, <sup>177</sup>Lu or <sup>90</sup>Y incorporated into tissue implantable depots.
Phys Med Biol. 2017 Oct 04;:
Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.
Methods. 2017 Jul 23;:
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with (177)Lu.
Pharm Res. 2016 Dec 16;
Depot system for controlled release of gold nanoparticles with precise intratumoral placement by permanent brachytherapy seed implantation (PSI) techniques.
Int J Pharm. 2016 Nov 3;:
Development and preclinical studies of (64)Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
MAbs. 2016 Nov 4;:0
(111)In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection.
Nucl Med Biol. 2016 Aug 24;43(12):818-826
Monte-Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of 64Cu - Comparison with MIRDcell S-Values and Implications for Studies of its Cytotoxic Effects.
J Nucl Med. 2016 Sep 22;
Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Mol Pharm. 2015 Nov 2;12(11):3963-72